Ozempic Pill Ingredient SNAC May Disrupt Gut Health in New Animal Study
Research finds the absorption enhancer in oral semaglutide tablets affects gut bacteria and inflammation markers beyond its intended role.
Summary
Scientists at Adelaide University discovered that SNAC, the ingredient that makes Ozempic and Wegovy work as pills, may have unintended biological effects. In a 21-day animal study, SNAC was linked to reduced beneficial gut bacteria, lower protective short-chain fatty acids, increased inflammation markers, and changes in brain-related proteins. SNAC is essential for oral semaglutide tablets because it protects the drug from stomach breakdown and helps absorption. While the study doesn't prove harm in humans, it raises questions about long-term daily exposure as pill versions become more popular than injections.
Detailed Summary
New research from Adelaide University reveals that SNAC (salcaprozate sodium), the absorption enhancer in oral Ozempic and Wegovy tablets, may affect the body beyond its intended function of helping semaglutide absorption. This matters because millions use these medications and oral versions are becoming increasingly popular due to convenience.
The 21-day animal study found several concerning changes: decreased beneficial gut bacteria that break down dietary fiber, reduced short-chain fatty acids that protect the gut lining, elevated blood inflammation markers, increased liver weight suggesting low-grade inflammation, and reduced levels of a brain protein linked to cognitive function. The cecum, where beneficial bacteria produce protective compounds, also became smaller.
SNAC is essential for oral semaglutide because it shields the drug from stomach enzymes and facilitates bloodstream entry. Without it, pill versions wouldn't work. The US recently approved oral Wegovy, potentially increasing daily SNAC exposure significantly as more patients choose pills over injections.
With obesity affecting one in eight people globally and semaglutide prescriptions rising rapidly, understanding all medication components becomes crucial. Lead researcher Amin Ariaee emphasizes that while these medicines are highly effective, long-term exposure effects of every ingredient need investigation.
Important caveats include that this was an animal study over just 21 days, and results don't prove human harm. However, the findings suggest SNAC's biological activity extends beyond simple absorption enhancement, warranting further research into long-term safety profiles of oral obesity medications.
Key Findings
- SNAC reduced beneficial gut bacteria and protective short-chain fatty acids in animal study
- Blood inflammation markers increased with repeated SNAC exposure over 21 days
- Brain protein levels associated with cognitive function decreased with SNAC treatment
- Liver weight increased, suggesting possible low-grade inflammatory response
- First systematic study of SNAC's biological effects beyond drug absorption
Methodology
This is a news report covering original research from Adelaide University. The study used animal models over 21 days to systematically investigate SNAC effects. Source appears credible from established university research.
Study Limitations
Animal study results may not translate to humans. Only 21-day exposure period studied, limiting long-term safety conclusions. No direct comparison with injectable semaglutide forms provided in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.